Pharmaceutical Preparations · SAN FRANCISCO, CA, United States
$22.16
+11.47% (+$2.28)2026-10-01
Smart-Money SignalAccumulation · 67/100— Insiders are net buyers over 90 days ($54.7M, 3 buys vs 0 sales)
Net Income-$29.3M
EPS$-4.61
Market Cap$167.0M
Price Performance
Historical data including institutional events
Company Profile
T
Travis Murdoch
CEO & Executive Director
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM.
The company was incorporated in 2024 and is headquartered in San Francisco, California.